ReviewAdvances in experimental medicine and biology2025
Global Treatment Approaches Part 1: Neuroprotection and Stem Cell Therapy.
Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Global treatment approaches, also called gene-agnostic therapies, are those that address pathophysiologic responses common to retinal degenerations, i.e., photoreceptor and RPE metabolic stress, dysfunction and, ultimately, cell death. Global treatment strategies may be classified as those that aim to maintain or replace dysfunctional photoreceptors and/or RPE (e.g., neuroprotective agents and stem cell therapies) or those that circumvent the dysfunctional photoreceptors entirely (e.g., bioelectronic retinal implants and optogenetics). The research and development costs of each gene-specific therapy are high relative to the number of individuals who can benefit from it. Gene agnostic treatments have the potential to benefit a significantly larger number of patients, including those for whom the genetic cause of their disease cannot be identified.
Indexed as
Identifiers
40736863What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.